title: Clinical analysis of malignant lymphomas of tonsils.
abstract: Data of 38 patients with primary tonsil lymphoma, treated during the past 14 years was analysed. All cases were non-Hodgkin lymphomas. There were 11 patients with Stage 1, 14 with Stage II, 8 with Stage III, and 4 with Stage IV tonsillar lymphomas. The applied chemotherapies were CHOP or MACOP-B regimen. The overall 5-year survival rate was 64.4%. Further analysis of the intermediate grade group showed that 5-year survival rates were 72.7%) for patients younger than 60 years old, in contrast to 35.0% for patients aged 60 or older (p 0.0049). Five-year survival rates were 100%) for Stage I, 32.4% for Stage II, 55.6% for Stage III, and 100%) for Stage IV patients (p = 0.0878). In patients with Stage II tonsillar lymphomas, 5-year survival rates were below 100% for CHOP regimen, 100% for MACOP-B regimen, 66.7% for radiation alone, and 0% for radiation followed by chemotherapy (p = 0.1966). In patients with Stage III tonsillar lymphomas, 5-year survival rates were below 100% for MACOP-B regimen, and 0% for initial radiation followed by chemotherapy (p = 0.2568). The factors influencing survival were age, stage, and treatment modality. For Stage I patients without bulky mass, radiation therapy is sufficient. For Stage II patients or Stage I patients with a bulky mass, CHOP regimen (followed by radiation) is the choice of treatment. For Stage III or IV patients,, MACOP-B regimen is promising.
authors.affiliation: Department of ORL, Nihon University, School of Medicine, Tokyo, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Endo
authors.forename: A
authors.initials: A
authors.lastname: Kida
authors.forename: U
authors.initials: U
authors.lastname: Sawada
authors.forename: M
authors.initials: M
authors.lastname: Sugitani
authors.forename: T
authors.initials: T
authors.lastname: Furusaka
authors.forename: Y
authors.initials: Y
authors.lastname: Yamada
authors.forename: H
authors.initials: H
authors.lastname: Iida
authors.forename: F
authors.initials: F
authors.lastname: Sakai
authors.forename: S
authors.initials: S
authors.lastname: Shigihara
authors.forename: H
authors.initials: H
authors.lastname: Niwa
authors.forename: T
authors.initials: T
authors.lastname: Yamazaki
authors.forename: Y
authors.initials: Y
authors.lastname: Kura
authors.forename: K
authors.initials: K
authors.lastname: Kikuchi
mesh_terms: D003131:Combined Modality Therapy; D004358:Drug Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007231:Infant, Newborn; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D014066:Palatine Tonsil / Q000473:pathology*; D015996:Survival Rate; D014067:Tonsillar Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy